A phase 1/2 study evaluating single-agent ivosidenib in frontline older and unfit patients with newly diagnosed IDH1-mutated AML reported an ORR of 42% and CR rate of 30% (ref. 68). This evidence concerns the gene IDH1 and acute myeloid leukemia.